ARTICLE
2 July 2024

Changing Legal Environment Adds Uncertainty To ACLA Lawsuit Against FDA Over LDT Rule

M
Mintz

Contributor

Mintz is a general practice, full-service Am Law 100 law firm with more than 600 attorneys. We are headquartered in Boston and have additional US offices in Los Angeles, Miami, New York City, San Diego, San Francisco, and Washington, DC, as well as an office in Toronto, Canada.
Of Counsel Benjamin Zegarelli spoke with GenomeWeb about an ACLA lawsuit against the FDA in connection with its final rule on laboratory-developed tests.
United States Food, Drugs, Healthcare, Life Sciences

Of Counsel Benjamin Zegarelli spoke with GenomeWeb about an ACLA lawsuit against the FDA in connection with its final rule on laboratory-developed tests.

Benjamin says, "My perspective on it is that the case for judicial deference to FDA under the current system without any changes would probably favor FDA's position to a certain extent. I'm not saying it would be a total slam dunk for FDA ... but the idea would be that under normal circumstances, as we've seen in the current state of jurisprudence, we should see courts deferring to FDA."

SOURCE

GenomeWeb

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More